Abstract:The activity of HIV-1 and its viral proteins within the central nervous system (CNS) is responsible for a wide array of neuropathological effects, resulting in a spectrum of neurocognitive deficits defined as HIV-associated neurocognitive disorders (HAND). Amongst the various viral proteins, the transactivator of transcription (Tat) remains detectable even with effective antiretroviral therapy (ART) and suppressed viremia, highlighting the significance of this protein in the modern ART era. Tat has been extensively researched in both fundamental and clinical settings due to its role in neuroinflammation, neuronal damage, and neurocognitive impairment amongst people living with HIV (PLHIV). To date, numerous fundamental studies have explored Tat-induced neuroinflammation. However, there is no clear consensus on the most frequently studied inflammatory markers or the consistency in the levels of these Tat-induced inflammatory marker levels across different studies. Therefore, we conducted a scoping review of studies investigating Tat-induced neuroinflammation. We conducted searches in PubMed, Scopus, and Web of Science databases using a search protocol tailored specifically to adhere to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for scoping reviews (PRISMA-ScR) guidelines. From the 22 included studies, findings suggest that the HIV-1 Tat protein amplifies levels of neuroinflammatory markers. Amongst the vast array of inflammatory markers explored in the included studies, consistent results point to higher levels of CCL2, IL-6, IL-8, and TNF-α in primary cells and cell lines exposed to or transfected with HIV-1 Tat. These markers are regulated by key inflammatory pathways, such as the extracellular signal-regulated kinase (ERK)1/2 mitogen-activated protein kinase (MAPK) pathway, the phosphatidylinositol 3-kinase (PI3K) pathway, the p38 MAPK pathway, and nuclear factor-kB (NF-kB). Furthermore, Tat has been shown to induce neuronal apoptosis, both directly and indirectly. With regards to study designs, utilizing full-length Tat101 at concentrations ranging from 100 to 1000 ng/ml and durations of 24 and 48 h appears optimal for investigating Tat-induced neuroinflammation. In this context, we highlight specific inflammatory markers and pathways that are potentially pivotal in Tat-induced neuroinflammation and subsequent neuronal damage. A deeper investigation into these markers and pathways is crucial to better understand their roles in the development of HAND.

Sulfated polymannuroguluronate, a novel anti-acquired immune deficiency syndrome drug candidate, blocks neuroinflammatory signalling by targeting the transactivator of transcription (Tat) protein.

Sulfated polymannuroguluronate, a novel anti-acquired immune deficiency syndrome drug candidate, decreased vulnerability of PC12 cells to human immunodeficiency virus tat protein through attenuating calcium overload.

Sulfated Polymannuroguluronate Inhibits Tat-induced SLK Cell Adhesion Via a Novel Binding Site, a KKR Spatial Triad

Sulfated polymannuroguluronate (SPMG), a novel anti-acquired immune deficiency syndrome (AIDS) drug candidate, inhibits T cell apoptosis via combating oxidative damage of mitochondria

Sulfated Polymannuroguluronate, a Novel Anti-Aids Drug Candidate, Inhibits HIV-1 Tat-induced Angiogenesis in Kaposi's Sarcoma Cells.

Sulfated Polymannuroguluronate, A Novel Anti-Aids Drug Candidate, Inhibits T Cell Apoptosis By Combating Oxidative Damage Of Mitochondria

Suppression Of Inflammatory Neurotoxins By Highly Active Antiretroviral Therapy In Human Immunodeficiency Virus-Associated Dementia

Inhibition of long-term potentiation by interleukin-8: implications for human immunodeficiency virus-1-associated dementia.

TAT-HSA-α-MSH fusion protein with extended half-life inhibits tumor necrosis factor-α in brain inflammation of mice

Protection Against Human Immunodeficiency Virus Type 1 Tat Neurotoxicity by Ginkgo Biloba Extract EGb 761 Involving Glial Fibrillary Acidic Protein.

Inhibitory Effects of Human Immunodeficiency Virus Gp120 and Tat on Cpg-A-Induced Inflammatory Cytokines in Plasmacytoid Dendritic Cells

Glutamate production by HIV-1 infected human macrophage is blocked by the inhibition of glutaminase.

Neuropathologies in Transgenic Mice Expressing Human Immunodeficiency Virus Type 1 Tat Protein under the Regulation of the Astrocyte-Specific Glial Fibrillary Acidic Protein Promoter and Doxycycline.

Unraveling the Mechanisms of Neurotoxicity in HIV Type 1-Associated Dementia: Inhibition of Neuronal Synaptic Transmission by Macrophage Secretory Products

Soluble Hiv-1 Infected Macrophage Secretory Products Mediate Blockade Of Long-Term Potentiation: A Mechanism For Cognitive Dysfunction In Hiv-1-Associated Dementia

Anti-tat Hutat2:Fc Mediated Protection Against Tat-Induced Neurotoxicity and HIV-1 Replication in Human Monocyte-Derived Macrophages

Molecular Mechanism(s) Involved in the Synergistic Induction of CXCL10 by Human Immunodeficiency Virus Type 1 Tat and Interferon-Γ in Macrophages

Potentiation of T Cell Function by a Marine Algae-Derived Sulfated Polymannuroguluronate: in Vitro Analysis of Novel Mechanisms.

Acute Administration of HIV-1 Tat Protein Drives Glutamatergic Alterations in a Rodent Model of HIV-Associated Neurocognitive Disorders

Transactivator of Transcription (Tat)-Induced Neuroinflammation as a Key Pathway in Neuronal Dysfunction: A Scoping Review

In vitro glutaminase regulation and mechanisms of glutamate generation in HIV-1-infected macrophage.